Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
Michelle L. O’Donoghue(Brigham and Women's Hospital), Marc S. Sabatine(Brigham and Women's Hospital), Julia Kuder(Brigham and Women's Hospital), J. Antonio G. López(Center for Global Development), Helina Kassahun(Amgen (United States)), Norman E. Lepor(University of California, Los Angeles), Beat Knüsel(Amgen (United States)), Huei Wang(National Taiwan University), Robert S. Rosenson(Mount Sinai Hospital), Seth J. Baum(Boca Raton Regional Hospital), You Wu(Center for Global Development), Sabina A. Murphy(Brigham and Women's Hospital), Bariş Gencer(University of Bern), Xinhui Ran(Brigham and Women's Hospital), Daniel Gaudet(Brigham and Women's Hospital), Elmer Stout(University Hospital of Geneva)
Cited by 513
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction
|New England Journal of Medicine|2015|2k